1.McFarland, LV, et al. Nosocomial acquisition of Clostridium difficile infection. New England Journal of Medicine 1989; 320: 204–210.
2.Kelly, CP, Pothoulakis, C, LaMont, JT. Clostridium difficile colitis. New England Journal of Medicine 1994; 330: 257–262.
3.Pepin, J, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. Canadian Medical Association Journal 2004; 171: 466–472.
4.Ricciardi, R, et al. Increasing prevalence and severity of Clostridium difficile colitis in hospitalized patients in the United States. Archives of Surgery 2007; 142: 624–631.
5.O'Connor, JR, Johnson, S, Gerding, DN. Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. Gastroenterology 2009; 136: 1913–1924.
6.Warny, M, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366: 1079–1084.
7.Miller, MA, et al. Morbidity, mortality, and healthcare burden of nosocomial Clostridium difficile-associated diarrhea in Canadian hospitals. Infection Control and Hospital Epidemiology 2002; 23: 137–140.
8.Kyne, L, et al. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clinical Infectious Disease 2002; 34: 346–353.
9.Muto, CA, et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infection Control and Hospital Epidemiology 2005; 26: 273–280.
10.Byun, TJ, et al. Clinical characteristics and changing epidemiology of Clostridium difficile-associated disease (CDAD). Korean Journal of Gastroenterology 2009; 54: 13–19.
11.Lee, JH, et al. The incidence and clinical features of Clostridium difficile infection; single center study. Korean Journal of Gastroenterology 2010; 55: 175–182.
12.Lee, YJ, et al. Change of Clostridium difficile colitis during recent 10 years in Korea. Korean Journal of Gastroenterology 2010; 55: 169–174.
13.Shin, BM, et al. Multicentre study of the prevalence of toxigenic Clostridium difficile in Korea: results of a retrospective study 2000–2005. Journal of Medical Microbiology 2008; 57: 697–701.
14.Shin, BM, et al. Emerging toxin A-B+ variant strain of Clostridium difficile responsible for pseudomembranous colitis at a tertiary care hospital in Korea. Diagnostic Microbiology and Infectious Disease 2008; 60: 333–337.
15.Kim, H, et al. Investigation of toxin gene diversity, molecular epidemiology, and antimicrobial resistance of Clostridium difficile isolated from 12 hospitals in South Korea. Korean Journal of Laboratory Medicine 2010; 30: 491–497.
16.Tae, CH, et al. The first case of antibiotic-associated colitis by Clostridium difficile PCR ribotype 027 in Korea. Journal of Korean Medical Science 2009; 24: 520–524.
17.McDonald, LC, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. New England Journal of Medicine 2005; 353: 2433–2441.
18.Kuijper, EJ, et al. Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008. Eurosurveillance 2008; 13.
19.Kato, H, et al. First isolation of Clostridium difficile O27 in Japan. Eurosurveillance 2007; 12: E0701113.
20.Kyne, L, et al. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. New England Journal of Medicine 2000; 342: 390–397.
21.Gravel, D, et al. Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program Study. Clinical Infectious Disease 2009; 48: 568–576.
22.Dubberke, ER, et al. Multicenter study of Clostridium difficile infection rates from 2000 to 2006. Infection Control and Hospital Epidemiology 2010; 31: 1030–1037.
23.Barbut, F, et al. A European survey of diagnostic methods and testing protocols for Clostridium difficile. Clinical Infectious Disease 2003; 9: 989–996.
24.Jung, SW, et al. Clinical aspects of rifampicin-associated pseudomembranous colitis. Journal of Clinical Gastroenterology 2007; 41: 38–40.
25.Lee, JK, et al. Comparative value of sigmoidoscopy and stool cytotoxin-A assay for diagnosis of pseudoemmbranous colitis. Intestinal Research 2005; 3: 61–67.
26.Pepin, J, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clinical Infectious Disease 2005; 40: 1591–1597.
27.Schroeder, MS. Clostridium difficile-associated diarrhea. American Family Physician 2005; 71: 921–928.
28.Peterson, LR, et al. Detection of toxigenic Clostridium difficile in stool samples by real-time polymerase chain reaction for the diagnosis of C. difficile-associated diarrhea. Clinical Infectious Disease 2007; 45: 1152–1160.
29.Delmee, M, et al. Laboratory diagnosis of Clostridium difficile-associated diarrhoea: a plea for culture. Journal of Medical Microbiology 2005; 54: 187–191.
30.Cohen, SH, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infection Control and Hospital Epidemiology 2010; 31: 431–455.